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 The combination of a Western-diet and
aortic banding results in a cardio-
metabolic heart failure phenotype in
Ossabaw swine.
 Ossabaw swine with cardio-metabolic
heart failure display cardiac dysfunction
at the whole heart and cellular levels.
 The left ventricle transcriptome showed
gene signatures consistent with pro-
inflammatory heart failure.
 Cardio-metabolic heart failure was
coupled with microvascular dysfunction in
the heart, skeletal muscle, and brain.
 Ossabaw swine with cardio-metabolic
heart failure are sedentary and obese with
liver dysfunction.https://doi.org/10.1016/j.jacbts.2019.02.004
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405SUMMARY
AB BAND ACRONYM S
AB = aortic-banded
CON = control
EDPVR = end-diastolic
pressureLvolume relationship
EF = ejection fraction
HF = heart failure
HFpEF = heart failure with
preserved ejection fraction
HFrEF = heart failure with
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MaThe development of new treatments for heart failure lack animal models that encompass the increasingly
heterogeneous disease profile of this patient population. This report provides evidence supporting the
hypothesis that Western Dietfed, aortic-banded Ossabaw swine display an integrated physiological,
morphological, and genetic phenotype evocative of cardio-metabolic heart failure. This new preclinical
animal model displays a distinctive constellation of findings that are conceivably useful to extending the
understanding of how pre-existing cardio-metabolic syndrome can contribute to developing HF.
(J Am Coll Cardiol Basic Trans Science 2019;4:404–21) © 2019 The Authors. Published by Elsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
ed ejection fractionreducIL1RL1 = interleukin 1 receptor-
like 1
LV = left ventricle
NF = nuclear factor
PTX3 = pentraxin-3
= Western DietH eart failure (HF) is currently among themost challenging issues facing the treat-ment of cardiovascular disease. Of the
approximately 6million patients with HF in the United
States, there is an approximately equal diagnosis of HF
with reduced ejection fraction (HFrEF) and HF with
preserved ejection fraction (HFpEF) (1–5). The disease
profile of HF patients is becoming more heteroge-
neous, often displaying various combinations of
numerous comorbidities, including obesity, metabolic
syndrome, diabetes, and hypertension. Although the
prevalence of HF is expected to increase during the
next 15 years, traditional treatments for HF have
remained largely unchanged over the last 20 years.
Furthermore, HFpEF patients are largely unrespon-
sive to standardized therapeutic approaches proven
effective for HFrEF (1,2,6–9). Thus, new therapeutic
targets for HF patients are desperately needed.
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has focused on the role of increased systemic
inflammation that results from common risk factors for
developing HF. This has prompted discussion
regarding the need to develop preclinical animal
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phenotype. A number of syndromes may predispose
patients to HF, including metabolic disease (e.g.,
obesity, insulin resistance), hypertension, renal dis-
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TABLE 1 Postmortem Analysis of Heart and Lung Morphology, and
PressureVolume Assessment of Resting Systolic and Diastolic LV Function
Gross Morphology
CON
(n ¼ 5)
WD-AB
(n ¼ 5)
t-Test
(p Value)
Body surface area (m2) 1.10  0.01 1.51  0.04* <0.0001
Tibia length (cm) 16.6  0.2 16.6  0.1 0.93
Lung weight (g) 236  11 294  12† 0.01
Heart weight (g) 157  4 229  6* <0.0001
LV+S weight (g) 107  2 150  4* <0.0001
RV weight (g) 28  2 46  2‡ <0.001
Atria weight (g) 21  2 33  1‡ <0.001
LV Function: Pressure–Volume
and Echocardiography
CON
(n [ 4 to 5)
WD-AB
(n [ 4 to 5)
t-Test
(p Value)
Systolic function
HR (beats/min) 94  17 80  8 0.49
LVESV (ml) 48  6 33  9 0.21
LVESP (mm Hg) 94  12 102  6 0.54
LVEF (%) 52  3 63  5 0.12
LV SV (ml) 50  2 51  5 0.83
LV SVI (ml/m2) 46  1 34  4§ <0.05
ESPVR (mm Hg/ml) 11  5 23  7 0.21
PRSW (mm Hg) 65  10 91  8 0.09
Diastolic function
LVEDV (ml) 98  6 84  12 0.34
LVEDP (mm Hg) 10  1 8  2 0.22
EDPVR (mm Hg/ml) 0.015  0.003 0.040  0.010§ <0.05
LV untwisting: apical early
diastolic rotation rate (/s)
112  6 94  4§ <0.05
LV global longitudinal late
diastolic strain rate (1/s)
1.1  0.1 1.8  0.1* <0.0001
Values are mean  SE. *p < 0.0001. †p < 0.01. ‡p < 0.001. §p < 0.05; for significantly different
versus control (CON).
Atria ¼ right + left atria; EDPVR ¼ end-diastolic pressurevolume relationship; ESPVR ¼ end-
systolic pressurevolume relationship; HR ¼ heart rate; LV ¼ left ventricular; LVEDP ¼ LV end-
diastolic pressure; LVEDV ¼ LV end-diastolic volume; LVEF ¼ LV ejection fraction; LVESP ¼ LV
end-systolic pressure; LVESV ¼ LV end-systolic volume; LV+S ¼ LV + septum; LV SV ¼ LV stroke
volume; LV SVI ¼ LV stroke volume index; PRSW ¼ preload recruitable stroke work; RV ¼ right
ventricle; WD-AB ¼ Western diet, aortic banded.
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406characterization of animal models of experimental HF
that include multisystem contributions to the overall
pathology are therefore critical to advancing the un-
derstanding of a growing population of HF patients
with multiple pre-existing comorbidities.SEE PAGE 422A number of previous reports from our laboratory
(and others) showed that Ossabaw swine, a unique
translational large animal model genetically predis-
posed to obesity and metabolic derangement, do not
develop HF from dietary intervention alone (10–17).
Furthermore, our laboratory previously published
numerous studies that examined the impact of aortic
banding alone (in the absence of comorbidities) on
developing disease in a separate preclinical swine
model of HF (18–27). Thus, the primary goal of this
study was to develop a swine model of experimental
cardio-metabolic HF. Specifically, our aim was to
determine whether the combination of dietary andpressure-overload interventions would produce a
cardio-metabolic HF phenotype. We hypothesized
Western Diet (WD)fed Ossabaw swine subject to
chronic cardiac pressure overload by aortic banding
would display physiological, morphological, and ge-
netic phenotypes relevant to patients with pre-
existing metabolic derangement who are at risk of
developing HF. We provide detailed integrated ana-
lyses that demonstrate the potential relevance of this
preclinical swine model for cardio-metabolic HF
(28,29).
METHODS
EXPERIMENTAL DESIGN. Two-month-old, intact fe-
male Ossabaw swine (15 to 20 kg, Ossabaw pigs were
generously provided by: 1) Michael Sturek, PhD, in
the Ossabaw Swine Resource, Comparative Medicine
Program at Purdue University and Indiana University
School of Medicine; and 2) Randall Prather, PhD, and
Eric M. Walters, PhD, in the National Swine Resource
and Research Center at the University of Missouri-
Columbia), were assigned into 2 groups: nonsham
sedentary control (CON) (n ¼ 5) and WD-fed aortic-
banded (WD-AB) with HF (n ¼ 7). Two animals were
lost in the WD-AB group as a result of not surviving
the aortic banding surgery at 6 months of age; both
animals weighed >50 kg at the time of surgery. We
believe this issue can be remedied through weight
control in the initial phases of obesity development,
given all WD-AB animals in the current study under
this specific weight threshold survived without sur-
gical complications following thoracotomy. A third
animal was lost to sudden cardiac death 1 week before
terminal experiments were scheduled in the WD-AB
group. Necrospy of this animal revealed complica-
tions due to renal infarction, pulmonary and hepatic
congestion, and a systemic inflammatory process.
Ultimately, outcome measures in the WD-AB group
were assessed in 4 to 5 animals.
The CON group ingested a standard chow diet
(5L80, Lab Diet; 3.03 kcal/g1; carbohydrate: 71%;
protein: 18.5%, and fat: 10.5%; 500 g/day), whereas
the WD-AB group was fed a WD (1,000 g/day) high in
fat, high-fructose corn syrup, and cholesterol (5B4L,
Laboratory Diet; 4.14 kcal/g1; carbohydrate: 40.8%
[17.8% of total calories from high-fructose corn
syrup]; protein: 16.2%; fat: 43%, 2% cholesterol wt/
wt) as previously reported (13–17). At 6 months of age,
aortic banding was used to induce HF as previously
described (19–23,25–27). A trans-stenotic systolic
gradient of approximately 70 mm Hg (72  2 mm Hg)
was achieved under anesthesia using phenylephrine
(intravenously 1 to 3 mg/kg/min) to maintain a distal
TABLE 2 Serial Echocardiographic Assessment of LV Morphology
CON (n ¼ 5) WD-AB (n ¼ 5)
RM ANOVAAge 6 months Age 8 months Age 12 months
Pre-AB
Age 6 months
Post-AB
Age 8 months
Post-AB
Age 12 months
Body weight (kg) 31  2 36  2 46  1††† 45  2*** 56  3***††† 76  3***††† ME group##
LVIDd (mm) 40  1 41  1 45  1† 37  1 42  1† 46  2†† ME time##
LVIDs (mm) 24  1 25  1 26  1 23  1 21  1 23  2 p ¼ 0.33
LV WTd (mm) 6.2  0.5 6.4  0.2 5.7  0.3 6.6  0.2 9.8  0.3***†† 9.7  0.5***†† Interaction‡
LV WTs (mm) 10.0  0.5 11.0  0.3 11.3  0.4 11.8  0.3** 14.8  0.3***†† 16.1  0.4***†† Interaction§
Values are mean SE. Statistics: Post hoc versus CON at the same time point (**p < 0.01; ***p < 0.001); main effect (ME) (##p< 0.0001); interaction effect¼ group time (§
p <0.01, ‡p < 0.001); †post hoc within same group versus 6-month time point (†p < 0.01; †† p < 0.001; p < 0.0001).
LVIDd ¼ left ventricular internal diastolic dimension; LVIDs ¼ left ventricular internal systolic dimension; LV WTd ¼ left ventricular diastolic wall thickness; LV WTs ¼ left
ventricular systolic wall thickness; RM ANOVA, repeated measure analysis of variance.
TABLE 3 Ingenuity Pathway and Gene Ontology Analyses of Induced Heart Failure-
Related Gene Pathways Expressed between CON and WD-AB Left Ventricle
Ingenuity Pathway Analysis, Top Toxicology Lists
Name p Value
Cardiac hypertrophy <0.0001
Increases renal damage <0.0001
Renal necrosis/cell death <0.0001
Cardiac fibrosis <0.0001
Liver proliferation <0.0001
Name Matched Gene Symbols p Value
Gene ontology, signaling pathways: heart failure
Cardiomyocyte differentiation
through BMP receptors
MYH7, MYH7B, NPPA, NPPB, BMP4,
BMP5
<0.0001
Hypertrophy model EIF4E, IL1R1, IFRD1, ATF3, VEGFA <0.001
Gene ontology, function-based analysis phenotype: heart failure
Cardiac fibrosis ACKR3, AHR, HEY2, PPARA, HOPX, PTGS2,
THBS4, CSRP3, MAPK8, PDL
<0.001
Gene ontology, diseases: heart failure
Myocardial infarction ABCA1, ALDH2, CCL2, CIITA, F13A1, HMGCR,
LDLR, NPPA, NPPB, PLAT, PROCR, PTGS2,
SELP, THBS4, TLR4, TNNT1, VEGFA
<0.0001
Dilated cardiomyopathy ADRA2C, ANKRD2, CCL2, CSRP3, KCNIP2, LAMA2,
MYH7, NPPA, NPPB, PDLIM3, PGM1, SUN2,
TNNI1, TNNT1, VCAM1
<0.0001
Pulmonary fibrosis CCL2, CD24, CTGF, CXCL8, MMP11, RGS1, SLN,
UBD, VCAM1
<0.01
Left ventricular
noncompaction
CSRP3, MYH7, MYH7B, PRDM16, YWHAE <0.01
Pulmonary hypertension ADORA3, BMP4, NPPA, NPPB, PDE4A, PLAT, VEGFA <0.01
Heart disease C3, HMGCR, MYH7, NPPA, NPPB, PPARA <0.05
Atrial fibrillation NPPA, NPPB, PLAT, SCN3B, SELP <0.05
Hypertrophic cardiomyopathy CSRP3, MYH7, NPPB, TNNT1 <0.05
BMP ¼ bone morphogenic protein; other abbreviations as in Table 1.
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407peripheral vascular mean aortic pressure of approxi-
mately 90 mm Hg (87  2 mm Hg) at a heart rate of
85 beats/min (84  3 beats/min). In total, Ossabaw
swine in the WD-AB group were subjected to 10
months of WD and 6 months of chronic cardiac pres-
sure overload. Body surface area was calculated as
previously published for swine (30,31). Animals were
fed once per day, and water was provided ad libitum.
All animal protocols were in accordance with the
Principles for the Utilization and Care of Vertebrate
Animals Used in Testing Research and Training and
approved by the University of Missouri Animal Care
and Use Committee.
STATISTICAL ANALYSIS. Data analyses were per-
formed using SPSS (version 19.0, IBM, Armonk, New
York) or SigmaStat (version 3.5, Systat Software, San
Diego, California). Linear regression was used to
examine the relationship between inflammatory bio-
markers and diastolic function. Group comparisons
were made using a Student’s t-test (32). Group com-
parisons for in vitro vascular function and serial ul-
trasound morphological experiments were made
using a repeated-measures analysis of variance
(group  dose and group  time, respectively). Group
differences revealed by analysis of variance were
found using Student Newman-Keuls post hoc anal-
ysis. Interobserver variability for ultrasound mea-
sures was evaluated using the intraclass correlation
coefficient in a 2-way random model (<0.40: poor
agreement; 0.40 to 0.75: good agreement; >0.75:
excellent agreement) (33). Power analyses were con-
ducted to determine the appropriate number of pigs
to detect differences between groups as recom-
mended by Kim and Seo (34) using the Sealed Enve-
lope Power Calculator (https://www.sealedenvelope.
com/power/continuous-superiority). For input, we
used published end-diastolic pressurevolume rela-
tionship (EDPVR) data reported in 6 CON and 7 AB
pigs (20) because of the well-establisheddevelopment of diastolic dysfunction in patients with
metabolic syndrome and the reputation of EDPVR as a
gold standard for measuring diastolic function. Sig-
nificance level was set to 5%, power to 80%, mean
outcome in control group ¼ 0.011, mean outcome in
experimental group ¼ 0.021, and standard deviation
¼ 0.004 (20). This power analysis indicated 4 swine
per group would be sufficient. All data are presented
FIGURE 1 Representative P-V Loops
Representative pressurevolume (P-V) loops at rest from individual control (CON) and Western diet, aortic-banded (WD-AB) animals.
EDPVR ¼ end-diastolic P-V relationship; ESPVR ¼ end-systolic P-V relationship.
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408as means  SE, and significance was reported at p <
0.10 and p < 0.05 levels (35,36).
See Supplemental Material for a comprehensive
account of all Methods utilized in the current study
(Supplemental Tables 1 to 3, Supplemental Figures 1
to 8, and Supplemental References).
RESULTS
CARDIAC REMODELING AND FUNCTION. Tables 1 to
3 and Figures 1 to 4 provide evidence supporting
functional, structural, and genetic characteristics
consistent with HF in the WD-AB group using echo-
cardiographic, pressurevolume, post-mortem
morphology, and RNA-seq techniques. Considering 1
independent variable was diet, tibia length was
examined to determine if normalization of the
morphometric data was necessary (37,38). Tibia
length was the same between groups, indicating that
differences in body weight and body surface area
between groups were observed in animals with
similar age-related growth (Table 1). Because there
were no significant differences in tibia length, abso-
lute heart and lung weights were used for group
morphological analyses (39). WD-AB animals dis-
played increased lung weight compared with the CON
group, with no differences in resting ejection fraction
(EF) (Table 1). Significant concentric left ventricular
(LV) hypertrophy was present in WD-AB animals, as
indicated by an increase in global hypertrophy (LV,
right ventricle, and atria) (Table 1) and increased LV
diastolic wall thickness 2 and 6 months post-aortic
banding that was dependent on the group at 8 and
12 months of age, respectively (Table 2) (group  timeinteraction; representative ultrasound images are
shown in Supplemental Figures 1A and 1B). There
were no differences in LV internal diastolic dimen-
sion or end-diastolic volume between groups (Tables 1
and 2). Analysis of aortic hemodynamics (proximal to
the AB in the WD-AB group) (Supplemental Table 1)
indicated WD-AB animals faced a greater afterload
compared with CON animals, which was evident 6
months post-aortic banding as significant increases in
both aortic systolic blood pressure and pulse
pressure.
Additional analysis of LV function resulted in para-
doxical findings with respect to systolic function.
Stroke volume (Table 1) and torsion (Supplemental
Figure 1D) relative to cardiac remodeling were
similar between groups. There was a trend toward
increased LV contractility (measured as preload
recruitable stroke work, shown by our laboratory
and others in AB swine) (20,23,24,40) in the WD-AB
group, which was observed in parallel with a
decreased stroke volume index (Table 1). Figure 2
outlines the potential contributions of individual
cardiomyocyte function to whole heart cardiac
dysfunction (representative traces of calcium tran-
sients and sarcomere length are presented in
Supplemental Figures 2A and 2B). Diastolic and sys-
tolic calcium and sarcomere length (Supplemental
Figures 2C and 2D), as well as calcium transient and
shortening amplitudes (Supplemental Figures 2E and
2F), were comparable between the CON and WD-AB
groups under both baseline and dobutamine (1 mM)
experimental conditions, which was consistent with
preserved systolic function at the whole organ level.
However, differences among groups were apparent in
FIGURE 2 Ossabaw Swine Fed A WD With Chronic Pressure Overload-Induced HF Show Impaired Individual Cardiomyocyte Function
(A) Systolic cardiomyocyte calcium and (C) shortening kinetics are faster under baseline pacing conditions in the WD-AB group, but (B and D) lack b-adrenergic reserve
in response to dobutamine. (E and F) Diastolic calcium reuptake (tau) and (G and H) relaxation rate kinetic reserve following exposure to dobutamine is impaired in WD-
AB cardiomyocytes. (I) Representative cardiomyocyte images show (J) cardiomyocyte t-tubule disorganization in WD-AB animals. (K) Representative line scans
illustrate spontaneous ryanodine receptor-mediated calcium (L) spark frequency and (M) amplitude were increased in the WD-AB group. *t-test versus CON
(*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). n ¼ 4 animals, 25 to 27 cells in the CON group; n ¼ 4 animals, 23 to 25 cells in the WD-AB group.
ANOVA ¼ analysis of variance; HF ¼ heart failure; other abbreviations as in Figure 1.
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FIGURE 3 Isolated Mitochondrial Function Is Compromised in Ossabaw Swine Fed a WD With Chronic Pressure Overload-Induced HF and Associated With
Decreased L4CL
(A) Mitochondrial dysfunction evident as impaired complex 1 and 2-dependent respiration and functional uncoupling of the respiratory chain and adenosine
triphosphate synthesis. (B to E) Susceptibility to calcium (Ca2þ)-induced mitochondrial permeability transition (an early indicator of mitochondrial dysfunction) was
increased in the WD-AB group. (B and C) Quantification of the area above the curve of the Ca2þ-induced swelling traces was increased in WD-AB animals. (D and E)
Conversely, Ca2þ-retention capacity was decreased in the WD-AB group. (F to H) The composition of (G) tetralinoleoyl cardiolipin (L4CL) to (F) total cardiolipin levels
was (H) decreased in WD-AB animals. *t-test versus CON (*p < 0.05; ** p < 0.01). n ¼ 4 for CON and WD-AB groups. ADP ¼ adenosine diphosphate; MG ¼ malate/
glutamate; other abbreviations as in Figures 1 and 2.
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FIGURE 4 Ossabaw Swine Fed a WD With Chronic Pressure Overload-Induced HF Exhibit Distinct Molecular Signatures Indicative
of LV Pathological Remodeling
(A) Left ventricular (LV) gene interactions between significant cardiac hypertrophy and cardiac fibrosis networks revealed by ingenuity
pathway analysis between CON and WD-AB animals. (B) Pentraxin-3 (PTX3) mRNA level is increased in the WD-AB group and (C) negatively
correlated with LV untwisting. WD-AB animals show a right and downward shift along this relationship compared with CON (þ ¼ individual
animal data points forming the regression line). (D) Interleukin 1 receptor-like 1 (IL1RL1) mRNA level was also increased in the WD-AB group
and (E) negatively correlated with LV untwisting. WD-AB animals again show a right and downward shift along this relationship compared
with CON (þ ¼ individual animal data points forming the regression line). (F) The collagen I/III mRNA ratio is increased in the WD-AB group.
(G) A decrease in the more compliant N2BA titin isoform is seen in WD-AB animals with representative samples from both the CON and WD-AB
groups presented alongside the bar graph. *t-test versus CON (*p < 0.05). n ¼ 3 for CON and WD-AB in Figure 4A. n ¼ 5 for the CON group
and n ¼ 4 for the WD-AB group in Figures 4B to 4G. Abbreviations as in Figures 1 and 2.
Continued on the next page
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411calcium transient and shortening kinetics, which
resulted in a loss in dobutamine-induced functional
kinetic reserve (Figures 2A to 2D). Decreases in car-
diomyocyte time to peak calcium (Figures 2A and 2B)
and shortening (Figures 2C and 2D) following dobut-
amine challenge were blunted in the WD-AB group
compared with the CON group, despite showing faster
cellular systolic kinetics under 0.5-Hz baseline pacingconditions. These combined data suggest that
although traditional indicators of systolic function
like EF appear normal, the means by which resting
systolic function is maintained is substantially
different in WD-AB animals.
Diastolic function was also impaired in both the
whole heart and individual cardiomyocytes in WD-AB
animals. The EDPVR was increased in the WD-AB
FIGURE 4 Continued
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412group (representative pressurevolume loops are
shown in Figure 1, and quantification is shown in
Table 1). This was observed in parallel with abnormal
LV diastolic mechanics, including decreased LV early
diastolic untwisting and increased LV late longitudi-
nal strain rate, which were indicative of both
impaired early diastolic filling and enhanced atrial
systole during late diastole, respectively (Table 1).
At the cellular level, dobutamine-induced enhance-
ment in diastolic kinetic parameters, including cal-
cium reuptake rate (Figures 2E and 2F) (tau) and
relaxation rate (Figures 2G and 2H), were lost in the
WD-AB group, although baseline (0.5 Hz) values were
similar between groups. In addition, cardiomyocyte t-
tubules were disorganized (Figures 2I and 2J), and
spontaneous ryanodine receptormediated calcium
spark frequency and amplitude were increased
(Figures 2K and 2L) in WD-AB animals versus CON
animals. In total, these data indicate functional and
structural changes at the organ and cellular levels
consistent with diastolic dysfunction.
Impaired myocardial relaxation might also have
been influenced by metabolic derangement in the LV.
Figure 3 shows LV mitochondrial dysfunction,
including decreased complex 1- and 2-dependentrespiration and trifluoromethoxy carbonylcyanide
phenylhydrazone (FCCP)-uncoupled maximal mito-
chondrial respiration (Figure 3A). Calcium-induced
mitochondrial swelling was exacerbated (Figures 3B
and 3C), and calcium retention capacity (Figures 3D
and 3E) was also decreased in WD-AB animals,
which both indicated increased susceptibility to
calcium-induced mitochondrial permeability transi-
tion. Shotgun lipidomic showed the proportion of
contribution of tetralinoleoyl cardiolipin to total
myocardial cardiolipin levels (Figures 3F to 3H)
(a phospholipid that consists of w80% of ventricular
cardiolipin in humans and is considered to reflect a
healthy phospholipid phenotype in the heart) (41)
was decreased in the WD-AB group. Collectively, ev-
idence of impaired LV mitochondrial energetics is
consistent with the development of HF (42).
To define the molecular signature associated with
the pathological state in the WD-AB heart, tran-
scriptome was profiled in LV tissues from WD-AB and
CON animals. As presented in Table 3 and Figure 4,
unbiased Ingenuity Pathway Analysis detected top
gene expression changes in the WD-AB group are
cardiac hypertrophy and cardiac fibrosis, which are
listed as the #1 and #4 top significant toxicology lists
FIGURE 5 Ossabaw Swine Fed a WD With Chronic Pressure Overload-Induced HF Demonstrate Skeletal Muscle and Brain Vascular Dysfunction in
Isolated Microvessels
Brachial artery ring preparations indicate (A) endothelial and (B) smooth muscledependent function is similar between the CON and WD-AB groups. Skeletal muscle
microvessel preparations show significant (C) endothelial, (D) metabolic, and (E) smooth muscledependent dysfunction in the WD-AB group. Carotid artery ring
preparations reveal (F) endothelial and (G) smooth muscledependent function is similar between the CON and WD-AB group. Cerebral microvessel preparations show
significant (H) endothelial, (I)metabolic, and (J) smoothmuscledependent dysfunction inWD-AB animals. *t-test versus CON (*p<0.05; **p<0.01; ***p<0.001). n¼
5 for the CON group, and n¼ 4 for the WD-AB group. Ach¼ acetylcholine; SM¼ skeletal muscle; SNP¼ sodium nitroprusside; other abbreviations as in Figures 1 and 2.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 4 , N O . 3 , 2 0 1 9 Olver et al.
J U N E 2 0 1 9 : 4 0 4 – 2 1 Preclinical Swine Model of Cardio-Metabolic HF
413(Table 3). Significant interaction between gene net-
works associated with cardiac dysfunction and
fibrosis are also identified and illustrated in
Figure 4A. Based on gene ontology analysis for the
differentially expressed genes, a significant enrich-
ment of several HF-related gene networks was found
in the WD-AB hearts, as highlighted by numerous
genes known to be implicated in HF-related cardiac
fibrosis and hypertrophic remodeling, such as NPPA,
NPPB, MYH7, as well as bone morphogenic proteins
and collagens (Table 3). In addition to these well-
known molecular markers for HF, a number of in-
flammatory genes were also implicated, including
pentraxin-3 (PTX3) (43,44) and interleukin 1
receptor-like 1 (IL1RL1) (44,45), which are indicators
of inflammation. The approximate 5-fold increase in
PTX3 reported by RNA-seq in WD-AB animals was
confirmed independently using quantitative real-
time polymerase chain reaction (Figure 4B), as was
an increase in IL1RL1 (Figure 4D). Cumulative group
data, represented by the regression line, also showed
a significant negative correlation between LV
untwisting and both PTX3 (Figure 4C) and IL1RL1
(Figure 4E) mRNA levels. Group means reflected aright and downward shift along this relationship in
the WD-AB group compared with the CON group,
which indicated that an increase in LV expression of
these markers of inflammation was associated with a
decline in LV diastolic mechanical function. Cardiac
remodeling in the WD-AB group was confirmed
separately by 2 different measures that could influ-
ence the stiffness of individual cardiomyocytes and/
or the whole heart: 1) an increase in the collagen I/III
mRNA ratio (Figure 4F) (indicative of potentially
increased extracellular matrix stiffness) (46); and 2) a
decrease in protein expression of the N2BA isoform of
titin (Figure 4G) (a more compliant isoform of the
large elastic sarcomeric protein) (47–51). Total LV
collagen protein was the same between the groups
and visualized by representative Masson’s trichrome
images (Supplemental Figure 3). This suggested that
differences in LV stiffness regulated by the extracel-
lular matrix might be more related to changes in its
composition (i.e., collagen isoform shift) as opposed
to a general accumulation of total fibrotic compo-
nents. Overall, these data are indicative of molecular
signatures consistent with cardio-metabolic disease
in the myocardium of WD-AB animals and suggest
FIGURE 6 Ossabaw Swine Fed a WD With Chronic Pressure Overload-Induced HF Exhibit a Systemic Inflammatory State Consistent With Common Comorbidities
Seen in Experimental HF
Animals in the WD-AB group were (A) obese, (B) inactive, and (C) insulin resistant (homeostatic model assessment of insulin resistance [HOMA-IR]). Dyslipidemia was
observed in WD-AB animals as indicated by (D) increased plasma cholesterol, (E) triglycerides, (F) low-density lipoproteins (LDL), and (G) 2-chlorostearate. (H and I)
Plasma liver enzymes were increased and evidence of (J; Masson’s trichrome stain) increased liver fibrosis were seen in the WD-AB group. *t-test versus CON (*p< 0.05;
**p < 0.01; ***p < 0.001). n ¼ 5 for CON and WD. Abbreviations as in Figures 1 and 2.
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414that molecular mechanisms potentially relevant to
HF are present in this model.
PERIPHERAL AND CENTRAL VASCULAR FUNCTION.
Microvascular dysfunction, reflected by impaired
vasodilatory capacity, was present in the skeletal
muscle, brain, and coronary resistance vessels of WD-
AB animals. Figure 5 shows conduit and resistance
vessel function from the skeletal muscle and brain
following exposure to endothelial (acetylcholine,
bradykinin, insulin) and smooth muscledependent
(sodium nitroprusside) vasodilators. Although
conduit vessel function from both peripheral vascularbeds was similar to the brachial artery (Figures 5A and
5B) and the carotid artery (Figures 5F and 5G) in the
CON group, endothelial, metabolic, and smooth
musclemediated vasodilatory capacity was impaired
in the resistance arteries from isolated skeletal muscle
(Figures 5C to 5E) and brain (Figures 5H to 5J) arterioles
in the WD-AB group (complete doseresponse curves
for resistance vessels are shown in Supplemental
Figures 4 to 5). In addition, in vivo evaluation of cor-
onary vascular function demonstrated that although
relative coronary blood flow was similar between
groups (Supplemental Figure 6A, measured in the left
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415anterior descending coronary artery), myocardial ox-
ygen extraction was greater in the WD-AB group
(Supplemental Figure 6B). This was associated with
impaired coronary resistance vessel vasodilatory ca-
pacity to the large conductance calcium-activated
potassium (BKCa) channel agonist NS-1619 in isolated
arterioles (Supplemental Figures 6C and 6D, a medi-
ator of arterial tone abundantly expressed in vascular
smooth muscle shown to provide protection against
excessive vasoconstriction) (24,52–54). Gene ontology
analysis revealed significant enrichment of several
molecular pathways related to vascular disease,
including atherosclerosis, microvascular complica-
tions, and peripheral vascular disease (Supplemental
Table 2). In summary, these data indicate endothe-
lial, metabolic, and smooth muscledependent
microvascular dysfunction dominate vascular
impairment in both the periphery and heart of WD-AB
animals, which is consistent with functional vascular
abnormalities seen in both cardio-metabolic disease
and HF.
COMORBIDITIES AND INFLAMMATION. Before aortic
banding, the body weight of WD-AB animals was
significantly increased compared with CON, which
indicated metabolic disease was developing at the
time of surgery. The data presented in Figures 6A to
6J and Table 2 show evidence of metabolic derange-
ment at the time terminal experiments were per-
formed. Specifically, obesity (body weight)
(Figures 6A, Table 2), inactivity (decreased animal
movement in the pen) (Figure 6B), insulin resistance
(homeostatic model assessment of insulin resistance)
(Figure 6C), and plasma hyperlipidemia (Figures 6D to
6G) (including chlorinated lipids [Figure 6G] associ-
ated with increased immune-derived reactive oxygen
species production, inflammatory signaling, and
endothelial dysfunction) (55–58) were seen in the
WD-AB group. Wound healing in the WD-AB group
following surgical intervention was excellent, and all
animals were ambulatory, eating, urinating, and
defecating normally within 1 week post-surgery.
Thus, the significant decrease in cage activity in
WD-AB animals was not related to our surgical pro-
cedures or other health concerns separate from the
aortic banding or dietary interventions. Increased
plasma liver enzyme levels and nonalcoholic fatty
liver disease (Figures 6H to 6J) (evident by the com-
bination of liver steatosis, inflammation, and fibrosis)
in WD-AB animals was also consistent with nonalco-
holic steatohepatitis as shown previously in WD-fed
Ossabaw swine by our laboratory (14). Several re-
ports indicate nonalcoholic steatohepatitis is related
to HF and LV diastolic dysfunction (59–63). Furtherexploration of group differences that examined
metabolic and renal disease, including immune
and inflammation-related signaling pathways and
phenotypes, were assessed using RNA-seq in LV
tissue and is presented in Supplemental Figures 7
and 8 and Supplemental Tables 1 to 3. Enhancement
of molecular pathways related to obesity, metabolic
syndrome, diabetes, fatty liver disease, glomerulo-
nephritis, and renal fibrosis were revealed following
gene ontology analysis (Supplemental Table 2). A
number of corresponding signaling pathways
(Supplemental Table 3) and genetic phenotypes
(Supplemental Table 4) highlighted immune and in-
flammatory involvement. Three of the top 5 signifi-
cant upstream regulators identified by ingenuity
pathway analysis indicated activation of well-known
signaling networks that contributed to systemic
inflammation, including tumor necrosis factor
(Supplemental Figure 7A) (p < 0.05), interferon-g
(Supplemental Figure 7B) (p < 0.05), and toll-like re-
ceptor 3 (Supplemental Figure 7C) (p < 0.05). Top
regulator effect gene networks that support activa-
tion (Supplemental Figure 8A) (p < 0.05), migration
(Supplemental Figure 8A, p < 0.05), and adhesion
(Supplemental Figure 8B) (p < 0.05) of immune cells
potentially influenced by NF-kB signaling pathways
(Supplemental Table 3, Supplemental Figure 8B)
(CHUK-inhibitor of NF-kB kinase subunit-a) were also
identified. Together, these findings suggest this pre-
clinical model displays a chronic inflammatory state
consistent with cardio-metabolic disease and HF.
DISCUSSION
This multidisciplinary research study showed that
Ossabaw swine fed a WD and subjected to chronic
cardiac pressure-overload exhibited functional,
structural, and genetic characteristics consistent with
cardio-metabolic HF. In this experimental setting,
WD-AB animals displayed a number of cardiac and
vascular features reminiscent of metabolic derange-
ment and HF, including comorbidities associated with
activation of the immune system and inflammation.
Collectively, these data indicated the combination of
traditional methods used to generate HF (i.e., diet,
aortic-banding) imposed on the unique genetic back-
ground of Ossabaw swine resulted in a translational
animal model with a distinctive constellation of find-
ings that are conceivably useful to extending the un-
derstanding of how pre-existing cardio-metabolic
syndrome can contribute to developing HF.
As hypothesized, WD-AB animals displayed cardiac
characteristics fundamental to HF, including tradi-
tional indicators, myocardial remodeling, diastolic
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416dysfunction, and signs of altered, but compensated
resting systolic function. Conventional markers of HF
were observed at both system and molecular levels as
shown by post-mortem, imaging, and molecular
signatures that highlighted pathological cardiac
remodeling (increased diastolic wall thickness), pul-
monary involvement, and classic HF-related genes
(e.g., natriuretic peptides, myosin heavy chain). Dia-
stolic dysfunction was evident at the whole heart
level in the WD-AB group by both an increase in the
EDPVR and mechanically via abnormal diastolic
strain measures, which implied difficulty filling dur-
ing early diastole, with attempts to compensate for
this deficiency by increasing the contributions of
atrial systole to overall LV filling (64–68). Increased
EDPVR and altered LV diastolic mechanics, observed
in parallel with increased aortic systolic pressure,
pulse pressure, and directionally consistent (but
nonsignificant) increases in mean arterial pressure,
effective arterial elastance, end-systolic elastance,
and a decreased effective arterial elastance/end-
systolic elastance ratio are evocative of HFpEF (69).
LV end-diastolic pressure may not be elevated in
early HFpEF (70,71); thus, our findings outline a
reasonable scenario in which both vascular and ven-
tricular stiffening could lead to the increase in the
wet lung weight observed in the WD-AB group in the
present study. In addition, an impaired ability of
cardiomyocytes to sequester calcium and relax during
diastole following b-adrenergic agonism signified a
decrease in cellular diastolic cardiac reserve. Molec-
ular signatures also indicated detrimental LV
remodeling, as verified by evidence of collagen and
titin isoform shifts, could increase the stiffness of the
myocardium in parallel with LV mitochondrial
dysfunction (via associated deficits in energetic need
impairing excitationcontraction coupling).
Although compensated at rest, physiological
assessment of systolic function indicated a number of
paradoxical findings in the whole organ and a lack of
cardiac reserve in isolated cardiomyocytes from the
WD-AB group. A specific example of this inconsis-
tency included no group differences in what would be
considered a normal EF (>50%), observed in parallel
with increased LV contractility (preload
recruitable stroke work) and reduced systemic
perfusion as indicated by the decreased stroke vol-
ume index. This contradiction also existed at the
cellular level in WD-AB animals, as individual car-
diomyocytes displayed normal absolute calcium
transient and shortening amplitude, yet had an
associated reduction in kinetic reserve capacity in
response to adrenergic challenge with dobutamine.
Such findings were consistent with those in rodentmodels of hypertrophy, in which cardiomyocyte
functional parameters are maintained or enhanced
(72,73), which may serve as an initial compensatory
mechanism used by the heart to maintain systolic
function at rest (74). However, such functional ad-
aptations might consume a large portion of the car-
diac reserve that normal healthy hearts typically
maintain. This functional compensation, disguised at
rest, becomes apparent during scenarios of increasing
cardiovascular stress (e.g., activities of daily living,
exercise), limiting the flexibility of the heart to
respond to increasing hemodynamic demand.
Together, this collection of data provides a solid
foundation of evidence supporting the presence of
experimental HF in WD-AB animals.
Increasing evidence suggests peripheral vascular
dysfunction also plays a significant role in the lack of
cardiovascular reserve and high prevalence of
cardiogenic dementia in patients with HF. Our results
indicate that at this stage of disease, a profile of pri-
marily microvascular dysfunction reminiscent of
HFpEF was observed in this translational model, as
opposed to impaired conduit artery function which is
more often associated with HFrEF (75–87). Novel data
from the WD-AB group indicated there was a signifi-
cant smooth muscle component to this profile of
functional microvascular impairment in multiple
vascular beds, including those supplying skeletal
muscle, the brain, and the heart. Vascular mecha-
nisms targeting smooth muscle may have therapeutic
value given smooth muscle-mediated vascular
dysfunction has been observed in resistance vessels
from both the heart and the brain of Ossabaw swine
with metabolic syndrome that did not have HF (88),
and aortic-banded Yucatan mini-swine that displayed
HF in the absence of metabolic comorbidities (24,26).
A good deal of focus has also been placed on endo-
thelial impairment caused by chronic inflammation as
a driving force behind the development of cardio-
metabolic syndrome and HF. Our results likewise
showed both endothelial and metabolic microvas-
cular dysfunction in WD-AB animals (again in multi-
ple vascular beds). A potential intersection between
smooth muscle and endothelial-dependent vascular
dysfunction could be nitric oxide, manifested via
impaired downstream cGMP/PKG signaling that could
negatively affect LV function from both a vascular
and myocardial perspective (44). Diminished micro-
vascular function, regardless of cellular mechanism,
could significantly impact a patient’s ability to engage
in normal activities of daily living via: 1) a limited
ability to increase blood flow to skeletal muscle and/
or the heart in response to increased metabolic de-
mand; or 2) by harming cognitive function potentially
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417leading to depression, dementia, and reduced thera-
peutic compliance. Together, these data indicate
vascular impairment in WD-AB animals is dominated
by microvascular dysfunction in multiple organs. We
provide new evidence of a significant smooth
musclemediated component to the disease process,
in addition to metabolic and endothelial-dependent
impairment. These findings are consistent with par-
adigms believed to reflect a scenario of cardio-
metabolic HF.
CLINICAL PERSPECTIVES. The combination of
multisystem genetic signatures, considered in par-
allel with a profile of metabolic disease, including
obesity, inactivity, and dyslipidemia, supports the
initial decision to use Ossabaw swine for this study
given their genetic predisposition to this cluster of
health disparities. From a molecular perspective,
mRNA transcriptome signatures from the LV support
our pathophysiological evidence of experimental HF
and extensive cardio-metabolic disease in the WD-
AB group. The molecular changes are highlighted
by genes and pathways that are also implicated in
numerous cardiac, vascular, metabolic, renal, im-
mune, and inflammation-related signaling pathways.
In particular, bone morphogenic proteinrelated
pathways and NF-kBmediated inflammatory gene
induction are stimulated by transforming growth
factor-b, tumor necrosis factor-a, and interleukin-1
signaling (89–91). These pathways, in addition to
IL1RL1 (also part of the IL-1 super family) (92,93),
were observed in the hearts of WD-AB animals. Anti-
inflammatory therapy, including interleukin-1 and
transforming growth factor-b inhibition, could be
tested in the preclinical cardio-metabolic HF model
presented here and contribute to the continuing
evaluation of these therapeutic targets, which are
currently being examined in clinical trials for both
HFrEF and HFpEF (94–97).
In addition, ingenuity pathway analysis revealed
significant gene signatures associated with activa-
tion, migration, and adhesion of immune cells
potentially regulated in part by Inhibitor of NFkB
Kinase Subunit Alpha (CHUK), a component of the
NFkB signaling complex that, counterintuitive to its
title, prompts activation of NFkB signaling (90,91).
Results from unbiased ‘-omics’-based analysis be-
tween groups indicate a strong role for NFkB
signaling in WD-AB animals, which can be activated
by chlorinated lipids such as 2-chlorostearate. Chlo-
rinated lipids can be generated from myeloperox-
idase, a protein expressed in neutrophils, monocytes,
and leukocytes that has been linked to inflammation
and endothelial dysfunction (55–57). Therapeutic
modulation of diet, including manipulation of lipidintake, has been linked to diastolic function and
cardiovascular risk in HFpEF patients (98–100). Our
results suggest this animal model could be a suitable
platform to examine nutritional interventions as a
way to modulate the pathological inflammation and
vascular dysfunction associated with cardio-
metabolic HF.
Systemic inflammation is highly correlated with
metabolic derangement, and our results also found
several gene networks reflecting inflammatory and
immune signaling pathways were induced in the
WD-AB group, including well-established molecular
targets such as tumor necrosis factor, interferon-g,
and toll-like receptor 3 (101–105). The finding of in-
flammatory markers, such as PTX3 and IL1RL1, may
also have potential diagnostic importance (43–45).
PTX3 has been correlated with diastolic dysfunction
(106,107), and IL1RL1 is mechanistically linked to the
regulation of myocardial fibrosis (104,105,108). Mo-
lecular validation of these targets in WD-AB animals,
and the association of PTX3 and IL1RL1 with LV
untwisting during early diastole, provides further
support of potential links between their levels and
impaired diastolic function. These relationships
warrant further mechanistic interrogation.
Other molecular targets that recently garnered
attention for their therapeutic potential to treat HF
include phosphodiesterase-9 (109) and histone
deacetylases such as HDAC9 (110). These mechanisms
appear as genes of interest in the cardiac hypertrophy
and fibrosis networks presented in Figure 4A that are
significantly altered in this translational model of
cardio-metabolic HF. Considered together, the results
of this study reveal a number of cellular mechanisms
potentially applicable to a cardio-metabolic pheno-
type characterized by diet and comorbidity-driven
inflammation. Accordingly, these data provide
numerous avenues of exploration that we believe
could be tested in this new preclinical platform of
cardio-metabolic HF.
STUDY LIMITATIONS. The assessment of cardiac
reserve is powerful as a diagnostic tool for assessing
HF. In the present study, we assessed cardiac reserve
at only the cellular level. Our group has a history of
using both exercise and dobutamine doseresponse
protocols in the catheter laboratory to assess cardiac
reserve in vivo (22–25,27,111–113). Although practical
considerations (including an extensive focus on the
transcriptome) limited our ability to perform these
experiments, examination of cardiac reserve in future
studies will be important to the continued verifica-
tion of HF in this model. A comprehensive examina-
tion of cardiomyocyte calcium fluxes was not
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
development of new treatments for HF has suffered
from a lack of animal models that encompass the
increasingly heterogeneous disease profile of this
patient population. This report provides evidence
supporting the hypothesis that WD-AB Ossabaw swine
displayed an integrated physiological, morphological,
and genetic phenotype evocative of cardio metabolic
HF.
TRANSLATIONAL OUTLOOK: This new preclinical
animal model displayed a distinctive constellation of
findings that are conceivably useful to extending the
understanding of how pre-existing cardio-metabolic
syndrome can contribute to developing HF.
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418performed, and the functional changes in calcium
handling proteins in this disease model remain to be
determined. We anticipate these changes are multi-
factorial based on our findings, and suggest complex
changes in expression and/or post-translational
modification of multiple calcium handling proteins.
The transcriptome results presented in this study
only suggest that certain molecular signatures in the
heart share the same profile as observed in other
diseases (e.g., renal pathology). By itself, the renal
RNA-seq data observed from LV samples was not
sufficient to establish etiology or mechanism, and
further interrogation of kidney disease and its rela-
tionship to developing HF is warranted. A strength of
this model is the statistical justification of a strong
pathological phenotype in the animals, despite the
large variability inherent to disease. Nevertheless,
more subtle phenotypes that could be of physiolog-
ical importance may be difficult to resolve with the
present study design, and follow-up studies will be
essential to extend the clinical translation of our
initial findings.
CONCLUSIONS
Our results indicate the combination of pressure-
overload and dietary intervention results in a profile
of cardio-metabolic HF in Ossabaw swine. This
unique preclinical animal model provides the oppor-
tunity to enhance our understanding of how meta-
bolic disease interacts with developing HF, as well as
a translational opportunity to develop new mecha-
nistic avenues of exploration relevant to pathological
conditions when symptoms of both cardio-metabolic
disease and HF are present.
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